Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18542270 | 0.85 | LY96 (0.74) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL3896955 | 0.84 | MAPT (0.54) | HDAC8HDAC3HDAC1LY96 | |
| SCHEMBL3896958 | 0.84 | MAPT (0.54) | HDAC8HDAC3HDAC1LY96 | |
| SCHEMBL3719964 | 0.83 | MAPT (0.55) | HDAC8LY96 | |
| SCHEMBL3719966 | 0.83 | MAPT (0.55) | HDAC8LY96 | |
| SCHEMBL3785272 | 0.83 | THRB (0.57) | HDAC8LY96 | |
| SCHEMBL3785276 | 0.83 | THRB (0.57) | HDAC8LY96 | |
| SCHEMBL20227828 | 0.81 | MAPT (0.54) | HDAC8LY96 | |
| SCHEMBL28061029 | 0.79 | MAPT (0.49) | HDAC8HDAC3HDAC1LY96 | |
| SCHEMBL16516669 | 0.79 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885HDAC3 9/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.